Clinical analyses have also established the connection between FBXL2 and EGFR such that expression of FBXL2 is reversely correlated with EGFR in NSCLC and that FBXL2 expression is reduced in NSCLC and is associated with poor clinical prognosis. This evidence concerns the gene EGFR and non-small cell lung carcinoma.